Serum urate home monitoring for gout using a Point-of-Care Testing Meter and nurse-led treat-to-target approach: A feasibility study
- Conditions
- gout1003754610023213
- Registration Number
- NL-OMON56711
- Lead Sponsor
- Sint Maartenskliniek
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Patients:
In order to be eligible to participate in this study, a patient subject must
meet all of the following criteria:
• Have a clinical diagnosis of gout
• Are older than 16 years of age
• Not at sUA target of 0.36 mmol/L (or 0.30 for tophaceous gout, chronic
arthropathy and frequent attacks), based on lab results not older than 6 weeks.
• Starting ULT (allopurinol, benzbromarone, febuxostat, probenecid or
pegloticase) or using ULT but not at sUA target
• Able and willing to sign informed consent
• Possession of a digital device (e.g. smartphone, laptop, tablet), email
address and in-ternet connection
• Willing to use a POCT at home
• Sufficient understanding of the Dutch language
Stakeholders:
In order to be eligible for the stakeholder interviews, a stakeholder must have
been involved in involved in carrying out, or managing the current study.
Patients who have contra indications for using urate-lowering therapry (ULT)
and not being able to measure sUA at home. Patients with mild kidney disease
(CKD-EPI between 0.45 and 0.90 ml/min/1.73m2) can be included but patients with
severe kidney disease (CKD-EPI < 0.45 ml/min/1.73m2) or severe liver function
problems (i.e. ALAT 3 times higher than normal range, liver cirrhosis etc.)
will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method